MedTrace Logo

Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B

NCT00877760 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2014-03-28

No results posted yet for this study

Summary

The purpose of this study is to investigate whether it is possible to augment the response of patients with HBeAg-positive chronic hepatitis B to entecavir by using a temporary peginterferon alpha-2a add-on strategy

Conditions

Interventions

DRUG

pegylated interferon a-2a

180 μg, once per week s.c. for 24 weeks

DRUG

Entecavir

0.5 mg once daily per os, either 72 weeks or 96 weeks

Sponsors & Collaborators

  • Foundation for Liver Research

    lead OTHER

Principal Investigators

  • Harry Janssen, Prof. dr. · Foundation for Liver Research (SLO) and Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • China
  • Netherlands
  • Poland
  • Romania
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00877760 on ClinicalTrials.gov